An official website of the United States government
Here’s how you know
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A
lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.
The Evidence-Based Practices Resource Center provides communities, clinicians, policy-makers and others with the information and tools to incorporate evidence-based practices into their communities or clinical settings.
This guide focuses on research supporting adaptations of evidence-based practices (EBPs) for under-resourced populations. Adaptations involve tailoring care, programs, and services to the cultural, social, gender, and demographic contexts of the people served to yield positive outcomes.
This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
This toolkit provides correctional administrators and health care providers recommendations and tools for implementing medication-assisted treatment (MAT) in correctional settings. It provides examples from the field that can be widely applied and adapted for programs that serve justice-involved individuals.
This guide developed by the American Society of Addiction Medicine (ASAM) provides healthcare providers with instant access to current guidelines in a clear concise format.
The American Society of Addiction Medicine (ASAM) developed this pocket guide for healthcare providers which provides instant access to key information in The ASAM Appropriate Use of Testing in Clinical Addiction Medicine in a clear and concise format.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine as part of medication-assisted treatment (MAT) for opioid use disorder.